Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158K | $31.4M | $16.1M | $169M | $88.0M | $138M | $243M | $241M | $3.55M | $829M |
| Revenue growth | — | 19736.5% | -48.6% | 945.7% | -47.9% | 57.2% | 75.9% | -1.0% | -98.5% | 23258.2% |
| Operating income | -$81.7M | -$37.0M | -$55.9M | $61.2M | -$93.2M | -$149M | -$179M | -$205M | -$601M | $98.3M |
| Operating margin | -51627.1% | -117.8% | -346.5% | 36.3% | -105.9% | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% |
| Net income | -$81.7M | -$34.4M | -$54.5M | $68.0M | -$84.6M | -$141M | -$176M | -$205M | -$599M | -$1.63M |
| Net margin | -51614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
| EPS (diluted) | -$1.34 | -$0.47 | -$0.65 | $0.69 | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.4M | -$23.9M | -$47.2M | $173M | -$95.8M | $171M | -$136M | -$154M | -$463M | $180M |
| Capital expenditures | $3.86M | $7.92M | $1.42M | $12.0M | $12.0M | $23.6M | $52.8M | $177M | $141M | $22.7M |
| Free cash flow | -$68.3M | -$31.9M | -$48.6M | $161M | -$108M | $148M | -$189M | -$331M | -$604M | $157M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85.4M | $24.8M | $30.1M | $222M | $144M | $184M | $108M | $111M | $103M | $227M |
| Total assets | $128M | $104M | $112M | $350M | $523M | $710M | $692M | $766M | $1.14B | $1.39B |
| Shareholders' equity | $95.6M | $81.4M | $95.8M | $245M | $462M | $409M | $399M | $271M | $185M | $466M |
| Retained earnings | -$398M | -$433M | -$487M | -$419M | -$504M | -$645M | -$821M | -$1.03B | -$1.63B | -$1.63B |
| Shares (wtd avg diluted) | 69.7M | 73.9M | 83.6M | 98.6M | 101M | 104M | 105M | 107M | 120M | 134M |
Every figure is extracted from ARROWHEAD PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.